Days at home, an emerging patient-centered outcome that quantifies time spent alive and out of health care facilities, has not been fully described in trials evaluating transcatheter aortic valve replacement (TAVR). We sought to compare the total number of days spent at home within the first year among intermediate-risk patients participating in a randomized clinical trial of TAVR with a self-expanding bioprosthesis vs surgical aortic valve replacement (SAVR).

In this comparative effectiveness research study, we performed a post hoc analysis between June 19, 2012, and June 30, 2018, of the Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients (SURTAVI) trial¹ linked to Medicare claims. The SURTAVI trial was a randomized clinical trial that occurred from June 19, 2012, to June 30, 2016, and involved data collected from 87 centers in the US, Europe, and Canada. Among 1660 participants in the present analysis, 355 (21.4%) were excluded (aged <65 years, index procedure at a Veterans Affairs or non-US hospital) and 1005 (60.5%) were successfully linked to Medicare claims as previously described.^2,3 This study was approved by the institutional review board at Beth Israel Deaconess Medical Center, Boston, Massachusetts, with a waiver of informed consent given the use of deidentified data.

在评估经导管主动脉瓣置换术 (TAVR) 的试验中，尚未完全描述在家中的天数，这是一种新兴的以患者为中心的结果，它量化了在医疗机构中度过的时间和离开医疗机构的时间。我们试图比较参加 TAVR 随机临床试验的中危患者在第一年内在家中度过的总天数与自膨胀生物瓣与外科主动脉瓣置换术 (SAVR)。

在这项比较有效性研究中，我们在 2012 年 6 月 19 日至 2018 年 6 月 30 日期间对与医疗保险索赔相关的中危患者手术或经导管主动脉瓣置换术 (SURTAVI) 试验^{1进行了事后分析。}SURTAVI 试验是一项随机临床试验，于 2012 年 6 月 19 日至 2016 年 6 月 30 日进行，涉及从美国、欧洲和加拿大的 87 个中心收集的数据。在本分析的 1660 名参与者中，355 名（21.4%）被排除在外（年龄 <65 岁，在退伍军人事务部或非美国医院进行索引程序），1005 名（60.5%）成功地与如前所述的医疗保险索赔相关联。^{2 ,3}这项研究得到了马萨诸塞州波士顿贝斯以色列女执事医疗中心的机构审查委员会的批准，由于使用了去识别的数据，因此放弃了知情同意。